IDT Form 4: 5,000 Deferred Stock Units Awarded to CTO with Price-Linked Conversion
Rhea-AI Filing Summary
IDT Corporation Chief Technology Officer David Wartell was granted 5,000 Deferred Stock Units (DSUs) on 09/18/2025. The DSUs vest ratably on 02/17/2026, 02/16/2027 and 02/15/2028, with optional deferral of the first two vesting dates by the recipient.
Each DSU converts to Class B common stock based on market price relative to the grant price of $50.90. Conversion ranges from a minimum of 0.5 shares to a maximum of 4.0 shares per DSU, so full vesting will result in issuance of between 2,500 and 20,000 Class B shares. Reported beneficial ownership after the grant is 5,000 Class B shares held directly.
Positive
- 5,000 DSU grant ties executive compensation to future stock performance through a market-price-linked conversion formula
- Ratable vesting over three years with deferral options supports executive retention
Negative
- Potential dilution of between 2,500 and 20,000 Class B shares upon full vesting, depending on future market price
Insights
TL;DR: Insider received 5,000 DSUs with market-priced conversion, creating potential issuance of 2,500–20,000 Class B shares upon vesting.
The grant is structured to tie payout to future stock price performance through a sliding conversion factor versus a fixed grant price of $50.90, which aligns compensation outcomes with shareholder value. Vesting is time-based over three years with deferral options for the first two vesting dates, providing retention incentives. The potential share issuance range (2,500–20,000) depends directly on future market prices and therefore produces variable dilution that is performance-linked rather than fixed.
TL;DR: The DSU award is a routine executive compensation tool with time-based vesting and price-linked conversion mechanics.
The award uses deferred stock units with conversion caps and minimums to moderate payout extremes while preserving upside alignment. The deferral options and ratable vesting are standard retention provisions. Disclosure is complete on vesting schedule, conversion formula, and grant price; there are no disclosed accelerated vesting conditions or payments tied to a change-in-control in this Form 4 filing.